The outcome of gemcitabine, sorafenib and S1 combination in the treatment of inoperable hilar cholangiocarcinoma

Trial Profile

The outcome of gemcitabine, sorafenib and S1 combination in the treatment of inoperable hilar cholangiocarcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Sorafenib
  • Indications Cholangiocarcinoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Nov 2016 Status changed from not yet recruiting to completed.
    • 28 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top